Oxyntomodulin long-acting - Pharmsynthez/Xenetic Biosciences

Drug Profile

Oxyntomodulin long-acting - Pharmsynthez/Xenetic Biosciences

Alternative Names: Oxyntolong; PSA-oxyntomodulin

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmsynthez; Xenetic Biosciences
  • Developer Pharmsynthez
  • Class Anorectics; Antihyperglycaemics; Gastrointestinal hormones; Obesity therapies; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 11 Jul 2016 Phase-II clinical trials in Obesity in Russia (SC) (Xenetic Biosciences pipeline, July 2016)
  • 11 Jul 2016 Phase-II clinical trials in Type-2 diabetes mellitus in Russia (SC) (Xenetic Biosciences pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top